Get the Stockscreener App
0.20
3.38%
-0.007
BiomX Inc stock is traded at $0.20, with a volume of 835.81K.
It is down -3.38% in the last 24 hours and down -63.64% over the past month.
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
See More
Previous Close:
$0.207
Open:
$0.21
24h Volume:
835.81K
Relative Volume:
0.13
Market Cap:
$2.16M
Revenue:
-
Net Income/Loss:
$-47.68M
P/E Ratio:
-0.00801
EPS:
-24.9619
Net Cash Flow:
$-23.09M
1W Performance:
-13.79%
1M Performance:
-63.64%
6M Performance:
-92.54%
1Y Performance:
-97.36%
1-Day Range:
$0.19
$0.21
1-Week Range:
$0.19
$0.232
52-Week Range:
$0.19
$13.70
BiomX Inc Stock (PHGE) Company Profile
Name
BiomX Inc
Sector
Industry
Phone
972 7 23942377
Address
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Compare PHGE vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.20 | 2.23M | 0 | -47.68M | -23.09M | -24.96 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-21 | Initiated | Ladenburg Thalmann | Buy |
BiomX Inc Stock (PHGE) Latest News
BiomX Inc. (NYSE: PHGE) seeks approval for Mandragola securities, $2M credit line and reverse split - Stock Titan
BiomX (PHGE) stock soars over 25% after-hours: Here's why it is trending - MSN
BiomX(PHGE) Stock Options Chain | Quotes & News - Moomoo
[EFFECT] BiomX Inc. SEC Filing - Stock Titan
BiomX signs LOI to acquire 60% of Israeli systems integrator Tsoock for $10.4M - MSN
BiomX Cancels Conversion Shares to Restore NYSE Compliance - TipRanks
BiomX cancels 1,013,637 conversion shares to regain NYSE American Section 712 compliance - TradingView
BiomX Inc. (NYSE: PHGE) cancels 1,013,637 shares tied to Dr. Frucht deal - Stock Titan
BiomX Dips on New Data Center - Baystreet.ca
BiomX: Zorronet Completes Transition to New Advanced Data Center Supporting Business Expansion and Enhanced AI Capabilities - The Manila Times
New Zorronet data center boosts real-time AI defense control - Stock Titan
BiomX Company Profile & Introduction - Moomoo
BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure - marketscreener.com
PHGE Q4 2025 Earnings: EPS Misses by a Wide Margin as Clinical Costs MountEarnings Forecast Report - DonanımHaber
BiomX (PHGE) Stock Soars Over 25% After-Hours: Here's Why it is Trending - Sahm
BiomX Unit Signs LOI to Buy 60% Stake in Tsoock for $10.4 Million - marketscreener.com
BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure and Secure-Site Integration Capabilities - marketscreener.com
BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform With Critical Infrastructure and Secure-Site Integration Capabilities - 富途牛牛
PHGE Q4 2025 Earnings: Significant EPS Miss of 73.75% as Clinical-Stage Biotech Reports No RevenueDownward Estimate Revision - dars.gov.et
BiomX: Subsidiary Zorronet Commences Installation and Operation of AI-Powered Detection Systems Under Israel Railways Agreement - AI Magazine
BiomX Subsidiary Zorronet Begins AI and ML Detection System Installation on Israel Railways Network - Moomoo
BiomX subsidiary starts AI track detection on Israel Railways network - Stock Titan
PHGE Q4 2025 Earnings: Significant EPS Miss Amid Development-Stage Company ChallengesPre-Announcement Alert - dars.gov.et
Price to book forward of BiomX Inc. – AMEX:PHGE - TradingView
PHGE Should I Buy - Intellectia AI
BiomX Inc. Announces Change in Certifying Accountant in SEC 8-K Filing – Key Details for Investors - Minichart
Auditor switch at BiomX (PHGE) as Barzily & Co. replaces PwC affiliate - Stock Titan
BiomX Inc. Financial Disclosures & SEC Filings - TradingView
BiomX (NYSE: PHGE) resale filing flags dilution, going concern risk - Stock Titan
BiomX Inc. Announces Amendment to 2026 Equity Incentive Plan: 5.46 Million Additional Shares Approved – SEC 8-K Filing Highlights – Minichart - Minichart
BiomX Shareholders Approve Director, Expand Equity Incentive Plan - TipRanks
BiomX (NYSE: PHGE) holders approve director and expand equity plan - Stock Titan
Transcript : BiomX Inc.Shareholder/Analyst Call - marketscreener.com
Price to sales forward of BiomX Inc. – BOATS:PHGE - TradingView
Enterprise value to EBIT forward of BiomX Inc. – BOATS:PHGE - TradingView
Enterprise value to revenue forward of BiomX Inc. – BOATS:PHGE - TradingView
Price to earnings forward of BiomX Inc. – BOATS:PHGE - TradingView
Enterprise value to EBITDA forward of BiomX Inc. – AMEX:PHGE - TradingView
BiomX Inc. Actuals & Estimates (AMEX:PHGE) - TradingView
BiomX’s DFSL brings 99% accurate counter-drone tech to ISC 2026 - Stock Titan
Enterprise value to EBITDA forward of BiomX Inc. – BOATS:PHGE - TradingView
BiomX, Next-Gen Counter Drone Solutions will be Showcased by DFSL at ISC 2026 - marketscreener.com
PHGE Q4 2025 Earnings: Wider-Than-Expected Loss Raises ConcernsPre-Announcement Alert - dars.gov.et
BiomX Stock (PHGE) Plunges 9.75%, Approaches Critical Support LevelFactor Timing - dars.gov.et
BiomX Announces DFSL to Showcase Next-Generation LADAR Counter-Drone and Perimeter Security Solutions at ISC 2026 - Quiver Quantitative
BiomX: Next-Gen Counter Drone Solutions will be Showcased by DFSL at ISC 2026 - GlobeNewswire
Biomx Inc (PHGE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BiomX Inc Stock (PHGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):